These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19755321)

  • 1. Biodegradable drug eluting stents: invasive and non-invasive imaging.
    Kukreja N; Otsuka M; van Mieghem C; Ligthart J; Sianos G; Serruys PW
    EuroIntervention; 2006 Nov; 2(3):403. PubMed ID: 19755321
    [No Abstract]   [Full Text] [Related]  

  • 2. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
    Byrne RA; Kastrati A; Massberg S; Wieczorek A; Laugwitz KL; Hadamitzky M; Schulz S; Pache J; Fusaro M; Hausleiter J; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2011 Sep; 58(13):1325-31. PubMed ID: 21920260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urethral in situ biocompatibility of new drug-eluting biodegradable stents: an experimental study in the rabbit.
    Kotsar A; Isotalo T; Uurto I; Mikkonen J; Martikainen P; Talja M; Kellomäki M; Salenius JP; Tammela TL
    BJU Int; 2009 Apr; 103(8):1132-5. PubMed ID: 19040531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents.
    Pan CJ; Tang JJ; Weng YJ; Wang J; Huang N
    Colloids Surf B Biointerfaces; 2009 Oct; 73(2):199-206. PubMed ID: 19541460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials.
    Stefanini GG; Byrne RA; Serruys PW; de Waha A; Meier B; Massberg S; Jüni P; Schömig A; Windecker S; Kastrati A
    Eur Heart J; 2012 May; 33(10):1214-22. PubMed ID: 22447805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE
    EuroIntervention; 2012 May; 8(1):117-9. PubMed ID: 22580255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No country for old stents? Improving long-term patient outcomes with biodegradable polymer drug-eluting stents.
    Byrne RA; Kastrati A
    Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):429-32. PubMed ID: 22458576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biocompatibility of new drug-eluting biodegradable urethral stent materials.
    Kotsar A; Nieminen R; Isotalo T; Mikkonen J; Uurto I; Kellomäki M; Talja M; Moilanen E; Tammela TL
    Urology; 2010 Jan; 75(1):229-34. PubMed ID: 19647295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome.
    Vassiliades TA; Douglas JS; Morris DC; Block PC; Ghazzal Z; Rab ST; Cates CU
    J Thorac Cardiovasc Surg; 2006 May; 131(5):956-62. PubMed ID: 16678575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and early clinical experience with a biodegradable polymer-based, rapamycin-eluting, Indian drug-eluting coronary stent: the BIO-RAPID study.
    Bhargava B; Karthikeyan G; Shankar PB; Seth S; Singh S; Pr U; Lal AV; Mohanty M
    Indian Heart J; 2008; 60(3):228-32. PubMed ID: 19240312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries.
    Buszman P; Milewski K; Zurakowski A; Pajak J; Liszka Ł; Buszman P; Musioł E; AbuSamra M; Trznadel S; Kałuza G
    Kardiol Pol; 2010 May; 68(5):503-9. PubMed ID: 20491008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug-eluting stents with biodegradable polymers.
    Van Der Giessen WJ; Van Beusekom HM
    Minerva Cardioangiol; 2011 Feb; 59(1):31-8. PubMed ID: 21285929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular imaging of drug-eluting coronary stents: method development, optimization and selected applications.
    Huang JT; Hannah-Qiuhua L; Szyszka R; Veselov V; Reed G; Wang X; Price S; Alquier L; Vas G
    J Mass Spectrom; 2012 Feb; 47(2):155-62. PubMed ID: 22359324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents.
    Gong F; Cheng X; Wang S; Zhao Y; Gao Y; Cai H
    Acta Biomater; 2010 Feb; 6(2):534-46. PubMed ID: 19607942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future.
    Leon MB; Bakhai A;
    Am Heart J; 2003 Oct; 146(4 Suppl):S13-7. PubMed ID: 14564301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.
    Roukoz H; Bavry AA; Sarkees ML; Mood GR; Kumbhani DJ; Rabbat MG; Bhatt DL
    Am J Med; 2009 Jun; 122(6):581.e1-10. PubMed ID: 19486720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
    Byrne RA; Kastrati A; Kufner S; Massberg S; Birkmeier KA; Laugwitz KL; Schulz S; Pache J; Fusaro M; Seyfarth M; Schömig A; Mehilli J;
    Eur Heart J; 2009 Oct; 30(20):2441-9. PubMed ID: 19720642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.